Citations

Citations to this article as recorded by  

• The role of adherence in patients with chronic diseases
  Michel Burnier
  European Journal of Internal Medicine.2024; 119: 1.     CrossRef
• Bempedoic acid: new evidence and recommendations on use
  Kristina Paponja, Ivan Pećin, Željko Reiner, Maciej Banach
  Current Opinion in Lipidology.2024; 35(1): 41.     CrossRef
• Genetic insights into repurposing statins for hyperthyroidism prevention: a drug-target Mendelian randomization study
  Anqi Huang, Xinyi Wu, Jiaqi Lin, Chiju Wei, Wencan Xu
  Frontiers in Endocrinology.2024;[Epub]     CrossRef
• Targeting host-specific metabolic pathways—opportunities and challenges for anti-infective therapy
  Monika I. Konaklieva, Balbina J. Plotkin
  Frontiers in Molecular Biosciences.2024;[Epub]     CrossRef
• Neutrophil Extracellular Traps (NETs) and Atherosclerosis: Does Hypolipidemic Treatment Have an Effect?
  Petros Adamidis, Despoina Pantazi, Iraklis Moschonas, Evangelos Liberopoulos, Alexandros Tselepis
  Journal of Cardiovascular Development and Disease.2024; 11(3): 72.     CrossRef
• Modulating effects of crocin on lipids and lipoproteins: Mechanisms and potential benefits
  Habib Yaribeygi, Mina Maleki, Farin Rashid-Farrokhi, Payman Raise Abdullahi, Mohammad Amin Hemmati, Tannaz Jamialahmadi, Amirhossein Sahebkar
  Heliyon.2024; 10(7): e28837.     CrossRef
• Assessing the Benefits of Lifestyle Influences on Cardiovascu-lar Health After Acute Coronary Syndrome
  Marius Rus, Claudia Elena Stanis, Paula Marian, Lilliana Oana Pobirci, Loredana Ioana Banszki, Veronica Huplea, Gheorghe Adrian Osiceanu, Bianca-Maria Pop, Gabriela Dogaru, Felicia Liana Andronie-Cioara
  Balneo and PRM Research Journal.2024; 15(Vol.15, no): 660.     CrossRef
• Liver cancer cells as the model for developing liver-targeted RNAi therapeutics
  Beibei Hou, Linhui Qin, Linfeng Huang
  Biochemical and Biophysical Research Communications.2023; 644: 85.     CrossRef
• Insights into Causal Cardiovascular Risk Factors from Mendelian Randomization
  C. M. Schooling, J. V. Zhao
  Current Cardiology Reports.2023; 25(2): 67.     CrossRef
• Secoisolariciresinol diglucoside and anethole ameliorate lipid abnormalities, oxidative injury, hypercholesterolemia, heart, and liver conditions
  Sana Noreen, Habib‐ur Rehman, Tabussam Tufail, Huma Badar Ul Ain, Chinaza Godswill Awuchi
  Food Science & Nutrition.2023; 11(6): 2620.     CrossRef
• Colesterol remanente, riesgo vascular y prevención de la arteriosclerosis
  Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán, Agustín Blanco, Mariano Blasco, José Luís Díaz Díaz, Ángel Díaz Rodríguez, Alipio Mangas, Vicente Pascual, Juan Pedro Botet, Pablo Pérez Martínez
  Clínica e Investigación en Arteriosclerosis.2023; 35(4): 206.     CrossRef
• Evolving Management of Low‐Density Lipoprotein Cholesterol: A Personalized Approach to Preventing Atherosclerotic Cardiovascular Disease Across the Risk Continuum
  Michael J. Wilkinson, Norman E. Lepor, Erin D. Michos
  Journal of the American Heart Association.2023;[Epub]     CrossRef
• The cell origins of foam cell and lipid metabolism regulated by mechanical stress in atherosclerosis
  Zhi Ouyang, Jian Zhong, Junyi Shen, Ye Zeng
  Frontiers in Physiology.2023;[Epub]     CrossRef
• Triglyceride-Rich Lipoprotein Metabolism: Key Regulators of Their Flux
  Alejandro Gugliucci
  Journal of Clinical Medicine.2023; 12(13): 4399.     CrossRef
• Remnant cholesterol, vascular risk, and prevention of atherosclerosis
  Xavier Pintó, Marta Fanlo, Virginia Esteve, Jesús Millán
  Clínica e Investigación en Arteriosclerosis (English Edition).2023; 35(4): 206.     CrossRef
• Antibiotics and Lipid-Modifying Agents: Potential Drug–Drug Interactions and Their Clinical Implications
  Marios Spanakis, Danny Alon-Ellenbogen, Petros Ioannou, Nikolaos Spernovasilis
  Pharmacy.2023; 11(4): 130.     CrossRef
• Advances in Treatment of Dyslipidemia
  Jill Dybiec, Wiktoria Baran, Bartłomiej Dąbek, Piotr Fularski, Ewelina Młynarska, Ewa Radzioch, Jacek Rysz, Beata Franczyk
  International Journal of Molecular Sciences.2023; 24(17): 13288.     CrossRef
• Peroxisome Proliferator-Activated Receptor α in Lipoprotein Metabolism and Atherosclerotic Cardiovascular Disease
  Elena Valeria Fuior, Evangelia Zvintzou, Theodosios Filippatos, Katerina Giannatou, Victoria Mparnia, Maya Simionescu, Anca Violeta Gafencu, Kyriakos E. Kypreos
  Biomedicines.2023; 11(10): 2696.     CrossRef
• Preparation, characterization and in vivo pharmacokinetic study of ginsenoside Rb1-PLGA nanoparticles
  Lixin Du, Huiling Lu, Yifei Xiao, Zhihua Guo, Ya Li
  Scientific Reports.2023;[Epub]     CrossRef
• Dysregulation of Cholesterol Homeostasis in Ovarian Cancer
  Zahraa Qusairy, Anne Gangloff, Shuk On Annie Leung
  Current Oncology.2023; 30(9): 8386.     CrossRef
• Riesgo residual. Conclusiones
  Ángel Cequier, José Luis Zamorano
  Revista Española de Cardiología Suplementos.2023; 23: 25.     CrossRef
• Causal effects of circulating lipids and lipid-lowering drugs on the risk of urinary stones: a Mendelian randomization study
  Zilong Tan, Jing Hong, Aochuan Sun, Mengdi Ding, Jianwu Shen
  Frontiers in Endocrinology.2023;[Epub]     CrossRef
• Bibliometric analysis of residual cardiovascular risk: trends and frontiers
  Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
  Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
• Current Understanding on the Genetic Basis of Key Metabolic Disorders: A Review
  Kenneth Francis Rodrigues, Wilson Thau Lym Yong, Md. Safiul Alam Bhuiyan, Shafiquzzaman Siddiquee, Muhammad Dawood Shah, Balu Alagar Venmathi Maran
  Biology.2022; 11(9): 1308.     CrossRef
• Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
  Joon Ho Moon, Kyuho Kim, Sung Hee Choi
  Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef

Citations

Citations to this article as recorded by  

• Pharmacological potential of ginseng and ginsenosides in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis
  Young-Su Yi
  Journal of Ginseng Research.2024; 48(2): 122.     CrossRef
• Fenofibrate alleviates NAFLD by enhancing the PPARα/PGC-1α signaling pathway coupling mitochondrial function
  Xuemei Wang, Jieying Wang, Cao Ying, Yuan Xing, Xuan Su, Ke Men
  BMC Pharmacology and Toxicology.2024;[Epub]     CrossRef
• Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
  Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
  Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
• Current Therapeutical Approaches Targeting Lipid Metabolism in NAFLD
  Manuela Vitulo, Elisa Gnodi, Giulia Rosini, Raffaella Meneveri, Roberto Giovannoni, Donatella Barisani
  International Journal of Molecular Sciences.2023; 24(16): 12748.     CrossRef
• PPARα agonist fenofibrate prevents postoperative cognitive dysfunction by enhancing fatty acid oxidation in mice
  Tiantian Liu, Xinlu Chen, Ziqi Wei, Xue Han, Yujia Liu, Zhengliang Ma, Tianjiao Xia, Xiaoping Gu
  Translational Neuroscience.2023;[Epub]     CrossRef
• Fenofibrate enhances lipid deposition via modulating PPARγ, SREBP-1c, and gut microbiota in ob/ob mice fed a high-fat diet
  Ying Zhang, Xiu-Bin Jia, Yun-Chao Liu, Wen-Qian Yu, Yan-Hong Si, Shou-Dong Guo
  Frontiers in Nutrition.2022;[Epub]     CrossRef

Fibrates, peroxisome proliferator-activated receptor-α agonists, are potent lipid-modifying drugs. Their main effects are reduction of triglycerides and increase in high-density lipoprotein levels. Several randomized controlled trials have not demonstrated their benefits on cardiovascular risk reduction, especially as an “add on” to statin therapy. However, subsequent analyses by major clinical trials, meta-analyses, and real-world evidence have proposed their potential in specific patient populations with atherogenic dyslipidemia and metabolic syndrome. Here, we have reviewed and discussed the accumulated data on fibrates to understand their current status in cardiovascular risk management.

Citations

Citations to this article as recorded by  

• Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study
  Nam Hoon Kim, Ji Yoon Kim, Jimi Choi, Sin Gon Kim
  European Heart Journal - Cardiovascular Pharmacotherapy.2024; 10(2): 118.     CrossRef
• Role of PPARα in inflammatory response of C2C12 myotubes
  Yuki Shimizu, Keiko Hamada, Tingting Guo, Chie Hasegawa, Yusuke Kuga, Katsushi Takeda, Takashi Yagi, Hiroyuki Koyama, Hiroshi Takagi, Daisuke Aotani, Hiromi Kataoka, Tomohiro Tanaka
  Biochemical and Biophysical Research Communications.2024; 694: 149413.     CrossRef
• Obicetrapib: Reversing the Tide of CETP Inhibitor Disappointments
  John J. P. Kastelein, Andrew Hsieh, Mary R. Dicklin, Marc Ditmarsch, Michael H. Davidson
  Current Atherosclerosis Reports.2024; 26(2): 35.     CrossRef
• Metabolic Flexibility of the Heart: The Role of Fatty Acid Metabolism in Health, Heart Failure, and Cardiometabolic Diseases
  Virginia Actis Dato, Stephan Lange, Yoshitake Cho
  International Journal of Molecular Sciences.2024; 25(2): 1211.     CrossRef
• ApoB100 and Atherosclerosis: What’s New in the 21st Century?
  Dimitris Kounatidis, Natalia G. Vallianou, Aikaterini Poulaki, Angelos Evangelopoulos, Fotis Panagopoulos, Theodora Stratigou, Eleni Geladari, Irene Karampela, Maria Dalamaga
  Metabolites.2024; 14(2): 123.     CrossRef
• Follistatin-like 1 (FSTL1) levels as potential early biomarker of cardiovascular disease in a Mexican population
  N. Ponce-Ruíz, J. F. Herrera-Moreno, A. E. Rojas-García, B. S. Barrón-Vivanco, C. A. González-Arias, Y. Y. Bernal-Hernández, L. Ortega-Cervantes, J. Ponce-Gallegos, J. A. Hernández-Nolasco, I. M. Medina-Díaz
  Heart and Vessels.2024;[Epub]     CrossRef
• Role of Fenofibrate Use in Dyslipidemia and Related Comorbidities in the Asian Population: A Narrative Review
  Chaicharn Deerochanawong, Sin Gon Kim, Yu-Cheng Chang
  Diabetes & Metabolism Journal.2024; 48(2): 184.     CrossRef
• Coenzyme Q10 in atherosclerosis
  Minjun Liao, Xueke He, Yangyang Zhou, Weiqiang Peng, Xiao-Mei Zhao, Miao Jiang
  European Journal of Pharmacology.2024; 970: 176481.     CrossRef
• Onion Polyphenols as Multi-Target-Directed Ligands in MASLD: A Preliminary Molecular Docking Study
  Maria Rosaria Paravati, Anna Caterina Procopio, Maja Milanović, Giuseppe Guido Maria Scarlata, Nataša Milošević, Maja Ružić, Nataša Milić, Ludovico Abenavoli
  Nutrients.2024; 16(8): 1226.     CrossRef
• Present and Future of Dyslipidaemia Treatment—A Review
  Iveta Merćep, Andro Vujević, Dominik Strikić, Ivana Radman, Ivan Pećin, Željko Reiner
  Journal of Clinical Medicine.2023; 12(18): 5839.     CrossRef
• VLDL receptor gene therapy for reducing atherogenic lipoproteins
  Ronald M. Krauss, Jonathan T. Lu, Joseph J. Higgins, Cathryn M. Clary, Ray Tabibiazar
  Molecular Metabolism.2023; 69: 101685.     CrossRef
• The emerging role of PPAR-alpha in breast cancer
  Zhiwen Qian, Lingyan Chen, Jiayu Liu, Ying Jiang, Yan Zhang
  Biomedicine & Pharmacotherapy.2023; 161: 114420.     CrossRef
• Molecular mechanisms and therapeutic perspectives of peroxisome proliferator‐activated receptor α agonists in cardiovascular health and disease
  Yujie Pu, Chak Kwong Cheng, Hongsong Zhang, Jiang‐Yun Luo, Li Wang, Brian Tomlinson, Yu Huang
  Medicinal Research Reviews.2023; 43(6): 2086.     CrossRef
• Macrophage angiotensin-converting enzyme reduces atherosclerosis by increasing peroxisome proliferator-activated receptor α and fundamentally changing lipid metabolism
  DuoYao Cao, Zakir Khan, Xiaomo Li, Suguru Saito, Ellen A Bernstein, Aaron R Victor, Faizan Ahmed, Aoi O Hoshi, Luciana C Veiras, Tomohiro Shibata, Mingtian Che, Lei Cai, Michifumi Yamashita, Ryan E Temel, Jorge F Giani, Daniel J Luthringer, Ajit S Divakar
  Cardiovascular Research.2023; 119(9): 1825.     CrossRef
• Rapid flow synthesis of fenofibrate via scalable flash chemistry with in-line Li recovery
  Sanket A. Kawale, Dong-Chang Kang, Gwang-Noh Ahn, Amirreza Mottafegh, Ji-Ho Kang, Gi-Su Na, Dong-Pyo Kim
  Chemical Engineering Journal.2023; 477: 147033.     CrossRef
• Effectiveness and Safety of Fenofibrate in Routine Treatment of Patients with Hypertriglyceridemia and Metabolic Syndrome
  Marat V. Ezhov, Gregory P. Arutyunov
  Diseases.2023; 11(4): 140.     CrossRef
• Development of New Genome Editing Tools for the Treatment of Hyperlipidemia
  Giulio Preta
  Cells.2023; 12(20): 2466.     CrossRef
• Exploring the hypolipidemic effects of bergenin from Saxifraga melanocentra Franch: mechanistic insights and potential for hyperlipidemia treatment
  Li Zhang, Yingying Tong, Yan Fang, Jinjin Pei, Qilan Wang, Gang Li
  Lipids in Health and Disease.2023;[Epub]     CrossRef
• Obesity and Dyslipidemia
  Barbora Nussbaumerova, Hana Rosolova
  Current Atherosclerosis Reports.2023; 25(12): 947.     CrossRef
• Bibliometric analysis of residual cardiovascular risk: trends and frontiers
  Lin Wang, Sutong Wang, Chaoyuan Song, Yiding Yu, Yuehua Jiang, Yongcheng Wang, Xiao Li
  Journal of Health, Population and Nutrition.2023;[Epub]     CrossRef
• Hypertriglyceridemia in Apoa5–/– mice results from reduced amounts of lipoprotein lipase in the capillary lumen
  Ye Yang, Anne P. Beigneux, Wenxin Song, Le Phuong Nguyen, Hyesoo Jung, Yiping Tu, Thomas A. Weston, Caitlyn M. Tran, Katherine Xie, Rachel G. Yu, Anh P. Tran, Kazuya Miyashita, Katsuyuki Nakajima, Masami Murakami, Yan Q. Chen, Eugene Y. Zhen, Joonyoung R.
  Journal of Clinical Investigation.2023;[Epub]     CrossRef
• Blood-Derived Lipid and Metabolite Biomarkers in Cardiovascular Research from Clinical Studies: A Recent Update
  Dipali Kale, Amol Fatangare, Prasad Phapale, Albert Sickmann
  Cells.2023; 12(24): 2796.     CrossRef
• Effective, disease-modifying, clinical approaches to patients with mild-to-moderate hypertriglyceridaemia
  Gary F Lewis, Robert A Hegele
  The Lancet Diabetes & Endocrinology.2022; 10(2): 142.     CrossRef
• Effects of Alirocumab on Triglyceride Metabolism: A Fat-Tolerance Test and Nuclear Magnetic Resonance Spectroscopy Study
  Thomas Metzner, Deborah R. Leitner, Karin Mellitzer, Andrea Beck, Harald Sourij, Tatjana Stojakovic, Gernot Reishofer, Winfried März, Ulf Landmesser, Hubert Scharnagl, Hermann Toplak, Günther Silbernagel
  Biomedicines.2022; 10(1): 193.     CrossRef
• Is there a role of lipid-lowering therapies in the management of fatty liver disease?
  Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
  World Journal of Hepatology.2022; 14(1): 119.     CrossRef
• Therapeutic Strategies and Chemoprevention of Atherosclerosis: What Do We Know and Where Do We Go?
  Ana Clara Aprotosoaie, Alexandru-Dan Costache, Irina-Iuliana Costache
  Pharmaceutics.2022; 14(4): 722.     CrossRef
• The Overlooked Transformation Mechanisms of VLCFAs: Peroxisomal β-Oxidation
  Qinyue Lu, Weicheng Zong, Mingyixing Zhang, Zhi Chen, Zhangping Yang
  Agriculture.2022; 12(7): 947.     CrossRef
• Current Trends of Big Data Research Using the Korean National Health Information Database
  Mee Kyoung Kim, Kyungdo Han, Seung-Hwan Lee
  Diabetes & Metabolism Journal.2022; 46(4): 552.     CrossRef
• New, Novel Lipid-Lowering Agents for Reducing Cardiovascular Risk: Beyond Statins
  Kyuho Kim, Henry N. Ginsberg, Sung Hee Choi
  Diabetes & Metabolism Journal.2022; 46(4): 517.     CrossRef
• Novel Targets for a Combination of Mechanical Unloading with Pharmacotherapy in Advanced Heart Failure
  Agata Jedrzejewska, Alicja Braczko, Ada Kawecka, Marcin Hellmann, Piotr Siondalski, Ewa Slominska, Barbara Kutryb-Zajac, Magdi H. Yacoub, Ryszard T. Smolenski
  International Journal of Molecular Sciences.2022; 23(17): 9886.     CrossRef
• Lipoprotein Lipase: Is It a Magic Target for the Treatment of Hypertriglyceridemia
  Joon Ho Moon, Kyuho Kim, Sung Hee Choi
  Endocrinology and Metabolism.2022; 37(4): 575.     CrossRef
• Fenofibrate add-on to statin treatment is associated with low all-cause death and cardiovascular disease in the general population with high triglyceride levels
  Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
  Metabolism.2022; 137: 155327.     CrossRef
• Alterations of HDL’s to piHDL’s Proteome in Patients with Chronic Inflammatory Diseases, and HDL-Targeted Therapies
  Veronika Vyletelová, Mária Nováková, Ľudmila Pašková
  Pharmaceuticals.2022; 15(10): 1278.     CrossRef
• Cardiovascular Risk Profile and Lipid Management in the Population-Based Cohort Study LATINO: 20 Years of Real-World Data
  Cristina Gavina, Daniel Seabra Carvalho, Marisa Pardal, Marta Afonso-Silva, Diana Grangeia, Ricardo Jorge Dinis-Oliveira, Francisco Araújo, Tiago Taveira-Gomes
  Journal of Clinical Medicine.2022; 11(22): 6825.     CrossRef
• New and emerging lipid-lowering therapy
  James M Backes, Daniel E Hilleman
  Future Cardiology.2021; 17(8): 1407.     CrossRef
• Systemic PFOS and PFOA exposure and disturbed lipid homeostasis in humans: what do we know and what not?
  Styliani Fragki, Hubert Dirven, Tony Fletcher, Bettina Grasl-Kraupp, Kristine Bjerve Gützkow, Ron Hoogenboom, Sander Kersten, Birgitte Lindeman, Jochem Louisse, Ad Peijnenburg, Aldert H. Piersma, Hans M. G. Princen, Maria Uhl, Joost Westerhout, Marco J. Z
  Critical Reviews in Toxicology.2021; 51(2): 141.     CrossRef
• A network pharmacology analysis on drug‐like compounds from Ganoderma lucidum for alleviation of atherosclerosis
  Ki Kwang Oh, Md. Adnan, Dong Ha Cho
  Journal of Food Biochemistry.2021;[Epub]     CrossRef
• Efficacy and Safety of Fenofibrate-Statin Combination Therapy in Patients With Inadequately Controlled Triglyceride Levels Despite Previous Statin Monotherapy: A Multicenter, Randomized, Double-blind, Phase IV Study
  Myung Soo Park, Jong-Chan Youn, Eung Ju Kim, Ki Hoon Han, Sang Hak Lee, Sung Hea Kim, Byung Jin Kim, Sung Uk Kwon, Kyu-Hyung Ryu
  Clinical Therapeutics.2021; 43(10): 1735.     CrossRef
• Prevalence of and Factors Associated With the Prescription of Fibrates Among Patients Receiving Lipid-Lowering Drugs in Germany
  Louis Jacob, Roger-Axel Greiner, Mark Luedde, Karel Kostev
  Journal of Cardiovascular Pharmacology.2021; 78(6): 885.     CrossRef
• Challenging Issues in the Management of Cardiovascular Risk Factors in Diabetes During the COVID-19 Pandemic: A Review of Current Literature
  Leili Rahimi, Mojtaba Malek, Faramarz Ismail-Beigi, Mohammad E. Khamseh
  Advances in Therapy.2020; 37(8): 3450.     CrossRef
• Treatment With Gemfibrozil Prevents the Progression of Chronic Kidney Disease in Obese Dahl Salt-Sensitive Rats
  Corbin A. Shields, Bibek Poudel, Kasi C. McPherson, Andrea K. Brown, Ubong S. Ekperikpe, Evan Browning, Lamari Sutton, Denise C. Cornelius, Jan M. Williams
  Frontiers in Physiology.2020;[Epub]     CrossRef
• Oxidative Stress and Inflammation in Renal and Cardiovascular Complications of Diabetes
  Amelia Charlton, Jessica Garzarella, Karin A. M. Jandeleit-Dahm, Jay C. Jha
  Biology.2020; 10(1): 18.     CrossRef

With a developing worldwide epidemic of diabetes mellitus, the renal complications associated with diabetes have become a serious health concern. Primary therapy for treating diabetic nephropathy is a multifactorial process. Peroxisome proliferator-activated receptor alpha (PPARα) agonists have been used primarily in clinical practice for the treatment of dyslipidemia and insulin resistance. Given that PPARα expression and regulation of metabolic pathways are involved in oxidative stress, inflammation, blood pressure regulation, and the renin-angiotensin aldosterone system, PPARα likely influences the development and pathogenesis of diabetic nephropathy via indirect effects on glucose and lipid homeostasis and also by direct action on the kidneys. These findings suggest that PPARα may become an important therapeutic target for treating diabetic renal complications.

Citations

Citations to this article as recorded by  

• The Proteome of Circulating Large Extracellular Vesicles in Diabetes and Hypertension
  Akram Abolbaghaei, Maddison Turner, Jean-François Thibodeau, Chet E. Holterman, Christopher R. J. Kennedy, Dylan Burger
  International Journal of Molecular Sciences.2023; 24(5): 4930.     CrossRef
• Metformin mitigates renal dysfunction in obese insulin-resistant rats via activation of the AMPK/PPARα pathway
  Laongdao Thongnak, Nattavadee Pengrattanachot, Sasivimon Promsan, Nichakorn Phengpol, Prempree Sutthasupha, Krit Jaikumkao, Anusorn Lungkaphin
  Archives of Pharmacal Research.2023; 46(5): 408.     CrossRef
• A comprehensive insight into the molecular and cellular mechanisms of the effects of Propolis on preserving renal function: a systematic review
  Paniz Anvarifard, Maryam Anbari, Alireza Ostadrahimi, Mohammadreza Ardalan, Zohreh Ghoreishi
  Nutrition & Metabolism.2022;[Epub]     CrossRef
• APX-115, a pan-NADPH oxidase inhibitor, protects development of diabetic nephropathy in podocyte specific NOX5 transgenic mice
  Eun Soo Lee, Hong Min Kim, Sun Hee Lee, Kyung Bong Ha, Yoon Soo Bae, Soo Jin Lee, Sung Hwan Moon, Eun Young Lee, Ji-Hye Lee, Choon Hee Chung
  Free Radical Biology and Medicine.2020; 161: 92.     CrossRef
• Fenofibrate decreased microalbuminuria in the type 2 diabetes patients with hypertriglyceridemia
  Xiaomeng Sun, Jia Liu, Guang Wang
  Lipids in Health and Disease.2020;[Epub]     CrossRef
• AMPK allostery: A therapeutic target for the management/treatment of diabetic nephropathy
  Kehinde Sulaimon Ayinde, Olamide Tosin Olaoba, Boyenle Ibrahim, Du Lei, Qian Lu, Xiaoxing Yin, Temitope Isaac Adelusi
  Life Sciences.2020; 261: 118455.     CrossRef
• Greater efficacy of atorvastatin versus a non-statin lipid-lowering agent against renal injury: potential role as a histone deacetylase inhibitor
  Ravi Shankar Singh, Dharmendra Kumar Chaudhary, Aradhana Mohan, Praveen Kumar, Chandra Prakash Chaturvedi, Carolyn M. Ecelbarger, Madan M. Godbole, Swasti Tiwari
  Scientific Reports.2016;[Epub]     CrossRef
• Upregulation of SIRT1-AMPK by thymoquinone in hepatic stellate cells ameliorates liver injury
  Yong Yang, Ting Bai, You-Li Yao, De-Quan Zhang, Yan-Ling Wu, Li-Hua Lian, Ji-Xing Nan
  Toxicology Letters.2016; 262: 80.     CrossRef
• Peroxisome proliferator-activated receptor α-dependent renoprotection of murine kidney by irbesartan
  Makoto Harada, Yuji Kamijo, Takero Nakajima, Koji Hashimoto, Yosuke Yamada, Hisashi Shimojo, Frank J. Gonzalez, Toshifumi Aoyama
  Clinical Science.2016; 130(21): 1969.     CrossRef
• Anthocyanin-rich Seoritae extract ameliorates renal lipotoxicity via activation of AMP-activated protein kinase in diabetic mice
  Eun Sil Koh, Ji Hee Lim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Bum Soon Choi, Hye Won Kim, Seong Yeon Hwang, Sae Woong Kim, Cheol Whee Park, Yoon Sik Chang
  Journal of Translational Medicine.2015;[Epub]     CrossRef
• Diabetic Kidney Disease: From Epidemiology to Clinical Perspectives
  Cheol Whee Park
  Diabetes & Metabolism Journal.2014; 38(4): 252.     CrossRef
• Peroxisome proliferator-activated receptor agonists in a battle against the aging kidney
  Marijn M. Speeckaert, Céline Vanfraechem, Reinhart Speeckaert, Joris R. Delanghe
  Ageing Research Reviews.2014; 14: 1.     CrossRef
• Fenofibrate and dipyridamole treatments in low-doses either alone or in combination blunted the development of nephropathy in diabetic rats
  Pitchai Balakumar, Rajavel Varatharajan, Ying Hui Nyo, Raja Renushia, Devarajan Raaginey, Ann Nah Oh, Shaikh Sohrab Akhtar, Mani Rupeshkumar, Karupiah Sundram, Sokkalingam A. Dhanaraj
  Pharmacological Research.2014; 90: 36.     CrossRef
• Differential effects of low-dose fenofibrate treatment in diabetic rats with early onset nephropathy and established nephropathy
  Supriya Kadian, Nanjaian Mahadevan, Pitchai Balakumar
  European Journal of Pharmacology.2013; 698(1-3): 388.     CrossRef
• Age-Associated Molecular Changes in the Kidney in Aged Mice
  Ji Hee Lim, Eun Nim Kim, Min Young Kim, Sungjin Chung, Seok Joon Shin, Hyung Wook Kim, Chul Woo Yang, Yong-Soo Kim, Yoon Sik Chang, Cheol Whee Park, Bum Soon Choi
  Oxidative Medicine and Cellular Longevity.2012; 2012: 1.     CrossRef
• Epidemiology of Obesity, the Metabolic Syndrome, and Chronic Kidney Disease
  Rikki M. Tanner, Todd M. Brown, Paul Muntner
  Current Hypertension Reports.2012; 14(2): 152.     CrossRef

Citations

Citations to this article as recorded by  

• The Differences of Metabolic Syndrome Risk Factors according to Obesity and Abdominal Obesity in Elderly Korean Women
  Kyung-A Shin
  The Korean Journal of Clinical Laboratory Science.2016; 48(4): 304.     CrossRef
• Effects of Soybean and DJI Chungkukjang Powder on Blood Glucose and Serum Lipid Reduction in db/db Mice
  Jae-Joon Lee, Ah-Ra Kim, Hae-Choon Chang, Hae-Ok Jung, Myung-Yul Lee
  Journal of the Korean Society of Food Science and Nutrition.2012; 41(8): 1086.     CrossRef
• Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
  Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
  BMB Reports .2010; 43(5): 337.     CrossRef
• Comparative analysis of fat and muscle proteins in fenofibratefed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein
  Jong-Ryeal Hahm, Jin-Sook Ahn, Hae-Sook Noh, Seon-Mi Baek, Ji-Hye Ha, Tae-Sik Jung, Yong-Jun An, Duk-Kyu Kim, Deok-Ryong Kim
  BMB Reports.2010; 43(5): 337.     CrossRef